Harrow Health Inc

Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development.The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Harrow Health Inc anticipates breakout year in 2023 post-successful Q4

Harrow Health Inc's Q4 2022 call showcased a strong performance, emphasizing strategic acquisitions and growth prospects for 2023. While challenges in expense management and pricing strategies exist, the company's leadership is focused on maximizing opportunities and delivering value to stakeholders.

Harrow Health Inc excels in Q1, poised for ophthalmic market leadership

Harrow Health Inc's Q1 2023 earnings call highlighted robust financial performance, a strategic roadmap for market leadership in ophthalmic pharmaceuticals, and positive early indicators for product success. While facing challenges in product formulations and margins, the company's focus on customer feedback and commercialization strategies presents significant growth opportunities.

Harrow Health Inc reports revenue growth driven by key products

Harrow Health Inc's Q2 2023 performance reflects positive revenue growth and a strong market position driven by VEVYE and IHEEZO.
While facing challenges with leverage ratios and net equity, the company's flexible approach and growth outlook offer opportunities for improvement.
Strengthened by recent acquisitions and stakeholder support, Harrow Health is poised for continued growth and market competitiveness.
Investors should monitor the company's financial leverage, revenue drivers, and market strategies for insights into its future performance.

Harrow Health Inc achieves record revenues, eyes market expansion

Harrow Health Inc reported strong financial performance with record revenues and growth in key metrics.
While facing challenges in certain product revenues and the compounding business, the company is optimistic about new product opportunities.
Management's confidence in the company's prospects and goals reflects a positive outlook for stakeholders.

Harrow Health Inc reports stellar Q4 results and eyes market dominance

Harrow Health Inc's Q4 2023 performance reflects robust financial growth, strategic successes, and a resilient market position, setting the stage for continued expansion.
While facing challenges such as a cyber attack impact and operational hurdles, the company's strengths in strategic focus, pricing strategy, and market opportunities position it well for future success.
With a clear vision for growth, a commitment to value creation, and a focus on market dominance in key segments, Harrow Health Inc is poised for sustained growth and profitability in the coming year.

Harrow Health Inc (HROW) achieves record Q3 revenue growth

Harrow Health Inc (HROW) reported strong Q3 performance with record revenue, driven by VEVYE and IHEEZO. The company is focused on sustainable growth, long-term vision, and value creation for stakeholders. Challenges include temporary inventory shortages and limited direct-to-consumer advertising plans.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced a favorable jury verdict in the case of ImprimisRx, LLC v. OSRX, Inc. ImprimisRx, a wholly owned subsidiary of Harrow, brought the lawsuit to a jury trial in a San Diego, California, federal court alleging willful acts of trademark infringement against OSRX, Inc. and its related party, Ocular Science, Inc. An eight-person jury in the United States District Court for.

Harrow's ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three investor conferences: Craig-Hallum 15th Annual Alpha Select Conference (Sheraton New York Times Square Hotel) November 19, 2024 1x1 Meetings Only BTIG 4th Annual Ophthalmology Day (Virtual) December 2, 2024 1x1 Virtual Meetings Only Piper Sandler 36th Annual Healthcare Conference (The Lotte New York Palace) Dec.

Harrow Announces Participation in Upcoming Investor Conferences

Harrow, Inc. (NASDAQ:HROW ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Jamie Webb - Director, Communications & Investor Relations Mark Baum - CEO Andrew Boll - CFO Conference Call Participants Chase Knickerbocker - Craig Hallum Brooks O'Neil - Lake Street Capital Markets Jeffrey Cohen - Ladenburg Thalmann & Company Mayank Mamtani - B. Riley Securities Operator Good morning, and welcome to Harrow's Third Quarter 2024 Earnings Conference Call.

Harrow, Inc. (HROW) Q3 2024 Earnings Call Transcript

Harrow (HROW) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.09 per share a year ago.

Harrow (HROW) Reports Q3 Loss, Lags Revenue Estimates

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the third quarter and nine months ended September 30, 2024. The Company also posted its third quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrow.com. The Company encourages all Harrow stockholders to review these documents, which provide additional details concerning the historical quarterly period and f.

Harrow Announces Third Quarter 2024 Financial Results

GoodRx Holdings

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced an innovative initiative to expand access and affordability for its ophthalmic pharmaceutical products. This effort includes a program of targeted price reductions for several Harrow products and a strategic partnership with GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., providing patients with discounts on select Harrow products. This.

Harrow Launches Access and Affordability Program with Price Reductions for Branded Products

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced its first major market access wins in the 2025 Medicare Part D Prescription Drug Program. Starting January 1, 2025, VEVYE will be included in key formularies managed by major plan sponsors such as Express Scripts, Cigna, Kaiser Permanente, and CVS Caremark. In the aggregate, these sponsors represent over 25 million Medicare Part D beneficiaries. In addition to Medic.

Harrow Announces Market Access Wins for VEVYE®

Harrow Inc. experienced a brief 20% stock drop in October but quickly recovered, showing resilience despite recent revenue channel underperformance. HROW's new branded pharmaceutical products, especially VEVYE, are driving a diversified revenue stream, with VEVYE showing exceptional growth and market penetration since its late 2023 launch. VEVYE's strong refill rates and expanding prescriber base indicate significant patient benefits and long-term revenue potential, supported by a patent extending to 2039.

Harrow: VEVYE And Its Impact On The DED Market

Harrow (HROW) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Harrow (HROW) is on the Move, Here's Why the Trend Could be Sustainable

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced the nationwide launch of a new digital patient access solution in collaboration with Asembia, a leading provider of specialty pharmacy and patient support hub services. This multi-year exclusive partnership is designed to expand access to Harrow's ophthalmic branded products, including FLAREX®, ILEVRO®, MAXIDEX®, MAXITROL®, NATACYN®, NEVANAC®, TOBRADEX® ST, VERKAZIA.

Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow's Branded Eyecare Products

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Harrow (HROW) Report Negative Earnings Next Week? What You Should Know

Orla Mining Ltd. 

HROW, ORLA and SWDBY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 6, 2024.

Best Momentum Stocks to Buy for November 6th

Clipper Realty

ORLA, SWDBY, SUOPY, HROW and CLPR have been added to the Zacks Rank #1 (Strong Buy) List on November 6, 2024.

New Strong Buy Stocks for November 6th

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the third quarter ended September 30, 2024, on Wednesday, November 13, 2024, after the market close. The Company will also post its third quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Thursday, Novembe.

Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024

Harrow (HROW) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Harrow (HROW) Upgraded to Strong Buy: What Does It Mean for the Stock?

The average of price targets set by Wall Street analysts indicates a potential upside of 26% in Harrow (HROW). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Harrow (HROW) Could Rally 25.95%: Here's is How to Trade

Amicus Therapeutics

FOLD, CLPR and HROW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 24, 2024.

Best Momentum Stocks to Buy for October 24th

GitLab

Trip.com

CLPR, HROW, FOLD, GTLB and TCOM have been added to the Zacks Rank #1 (Strong Buy) List on October 24, 2024.

New Strong Buy Stocks for October 24th

Harrow (HROW) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Recent Price Trend in Harrow (HROW) is Your Friend, Here's Why

abrdn Life Sciences Investors 

XOMA

There are sectors that experience demand irrespective of economic climate. I like cold hard cash placed in my account. We discuss big dividends from healthcare, yields +8.3%.

I Am Banking On The Silver Tsunami With Big Dividends

Harrow (HROW) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Harrow (HROW) Surges 8.4%: Is This an Indication of Further Gains?

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced the relaunch of TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative‑free synthetic corticosteroid that is approved by the U.S. Food and Drug Administration (FDA) for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids. In commenting on the announcement, Mar.

Harrow Relaunches TRIESENCE®

Shares of Harrow Inc (HROW, Financial) surged 3.26% in mid-day trading on Oct 2. The stock reached an intraday high of $46.10, before settling at $45.90, up from its previous close of $44.45.

Harrow Inc (HROW) Shares Up 3.26% on Oct 2

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Tennessee Governor Bill Lee, Department of Economic and Community Development Commissioner Stuart C. McWhorter, and Mark L. Baum, Chief Executive Officer of Harrow, Inc. (Nasdaq: HROW), announced today that Harrow is expanding its corporate headquarters in Nashville. Harrow was originally founded in 2012 in San Diego, California. In 2019, Harrow relocated its corporate headquarters to Nashville, Tennessee. Since 2019, Harrow has continued to invest in Nashvill.

Harrow Announces Nashville Expansion

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three investor conferences in September in New York: H.C. Wainwright 26th Annual Global Investment Conference (Lotte New York Palace Hotel) September 9-11, 2024 Company will present at 8:00 a.m. ET on September 10, 2024 Lake Street 8th Annual Best Ideas Growth Conference – Big 8 (The Yale Club) September 12, 2024 1x1.

News for Harrow Health Inc Stock (HROW)